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On admission, she was hemodynamically stable, with paleIntroduction
The authors report a case of pernicious anemia presenting
with normocytosis, “nonthyroidal illness syndrome” (NTIS)
and elevated cancer antigen 15.3 (CA 15.3).
Megaloblastic anemia is caused by defects in DNA synthe-
sis and typically presents with macrocytosis. One of its causes
is low serum vitamin B12 (cobalamin) levels, caused in 20–50%
of the cases by a decrease in intrinsic factor due to atrophy of
the gastric mucosa and consequently loss of parietal cells −
an autoimmune condition known as pernicious anemia.1,2
CA 15.3, a serum tumor marker, is a mucinous antigen
of the Mucin 1 (MUC-1) glycoprotein that is expressed by
epithelial cells (mainly breast epithelial cells) and erythroid
precursors (it is absent in mature erythrocytes).3 Its eleva-
tion is mainly associated with breast adenocarcinoma, but
it can also be found in other cancers and in some benign
3–5diseases.
NTIS is a condition in which there are abnormal thyroid
function tests in a patient without thyroid disease due to an
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reserved.adaptive response an adaptive response in order to minimize
to minimize the catabolism rate during high-stress periods.
It usually presents with decreased free triiodothyronine (FT3)
and thyroid-stimulating hormone (TSH) and normal free thy-
roxine (FT4).6,7
Case  report
Herein, the case of a 44-year-old female patient admitted to
the Emergency Room with complaints of asthenia and dys-
pepsia for three months is reported. There were no other
associated symptoms, such as fever, weight loss or hem-
orrhage. The patient denied alcohol, tobacco or substance
abuse, regular medications, dietary restrictions, prior blood
transfusions or any other relevant medical or surgical event.
Epidemiological and family data were irrelevant.94-001 Figueira da Foz, Portugal.
mucosa and icteric sclera; the remaining physical exami-
nation, including cardiac and pulmonary auscultation, and
abdominal and cervical palpation, was unremarkable.
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Table 1 – Evolution of analytical parameters.
Reference
values
At admission 6 months
later
Erythrocytes (× 106/L) 4.2–5.4 2.05 4.71
Hematocrit (%) 37.0–47.0 20.2 38.4
Hemoglobin (g/dL) 12.5–16.0 6.8 13.1
MCV (fL) 78.0–100.0 98.4 81.5
MCH (pg) 27.0–31.0 33.1 26.4
RDW (%) 11.5–14.0 29.9 15.2
Leucocytes (× 103/L) 4.0–10.5 3.72 6.06
Platelets (× 103/L) 150–450 136 264
Ferritin (ng/mL) 4.63–204 117.2 123.5
Vitamin B12 (pmol/L) 141–489 40.0 740.9
TSH (IU/mL) 0.27–4.2 0.02 1.92
FT3 (pg/mL) 2.5–4.3 0.81 3.67
FT4 (ng/dL) 0.93–1.7 1.37 1.57
CA 15.3 (IU/mL) <26.4 126.5 17.4
MCV: mean corpuscular volume; MCH: mean corpuscular
hemoglobin; RDW: red blood cell distribution width; TSH:
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hormone responses represent an adaptive and normal, physi-thyroid-stimulating hormone; FT3: free triiodothyronine; FT4:
free thyroxine; CA 15.3: cancer antigen 15.3.
The blood count revealed a normocytic normochromic
nemia [hemoglobin (Hb): 6.8 g/dL; mean corpuscular vol-
me (MCV): 98.4 fL], with reduced leukocyte (3.72 × 103/L),
latelet (136 × 103/L) and reticulocyte (26.2 × 103/L; index
.63%) counts. The peripheral blood smear showed anisopoik-
locytosis, hypersegmented neutrophils and no blasts.
The serum level of total vitamin B12 was markedly
ecreased (40.0 pmol/L), with normal folic acid, and iron
tores (ferritin: 117.2 ng/mL; erythrocyte sedimentation rate:
0 mm/h).
The patient had unconjugated hyperbilirubinemia, ele-
ated lactate dehydrogenase (LDH) (4788 IU/L; normal:
40–480), and low haptoglobin (0.3 mg/dL; normal: 30–200).
o changes in liver proﬁle enzymes, kidney function or
lectrolyte balance were detected. The direct Coombs test
as negative (Table 1).
A bone marrow aspirate smear revealed hypercellular-
ty, with hyperplasia and immaturity of erythroid lineage,
egaloblastosis, giant metamyelocytes and hypersegmented
eutrophils, ﬁndings consistent with megaloblastic anemia.
FT3 and TSH were decreased, while FT4 and thyrotropin-
eleasing hormone (TRH) were normal. The investigations
or infections by cytomegalovirus, Epstein Barr virus and
arvovirus B19 were negative. Nuclear, anti-dsDNA, and anti-
hyroid autoantibodies were also negative.
Available tumor markers for the most probable tumors
or gender and age (carcinoembryonic antigen, CA-125
nd CA 15.3) were assessed, identifying an increase in CA
5.3 (126.5 U/mL; normal: <26.4). In order to exclude an
ccult malignancy, low-radiation radiological studies (chest
adiography, mammography and thyroid, abdominal, pelvic
nd breast ultrasounds) were performed, that revealed no
nomalies.
Gastric parietal cell antibodies were positive and anti-
ntrinsic factor antibodies were negative. Gastric endoscopy
nd biopsies showed an atrophic pangastritis, without
elicobacter pylori infection, corroborating the diagnosis of per-
icious anemia. 1 5;3  7(6):414–416 415
The patient’s previous blood counts had revealed persistent
microcytosis (MCV 80 fL), Hb (11.5–12.5 g/dL), and normal fer-
ritin. High-performance liquid chromatography (HPLC) of Hb
was normal (Hb A2: 2.9%; Hb F: 0.3%) excluding -thalassemia.
We did not perform other Hb studies, namely -thalassemia.
The patient received 2000 g of intramuscular cyanocobal-
amin plus two units of packed red blood cells (due to marked
complaints of tiredness) and was referred to the Internal
Medicine Outpatient Clinic, with monthly administrations of
1000 g of cobalamin.
At the control appointment, six months after the begin-
ning of the treatment, a complete resolution of symptoms had
occurred, and laboratory abnormalities had normalized. How-
ever, MCV and mean corpuscular hemoglobin decreased to the
lower limit, which suggests a concomitant cause of microcy-
tosis (Table 1).
Discussion
Although the diagnosis of megaloblastic anemia is usually
easy to suspect after reviewing the complete blood count and
peripheral blood smear, the absence of macrocytosis, usually
due to a concomitant cause of microcytosis (such as tha-
lassemia or iron deﬁciency), could delay the diagnosis.1,8,9
In this case, ineffective erythropoiesis was suspected
due to the unconjugated hyperbilirubinemia, elevated LDH,
and decreased haptoglobin; the negative direct Coombs test
excluded an autoimmune etiology for this hemolytic anemia.
Low vitamin B12 levels, positivity for gastric parietal cell anti-
bodies and stomach biopsy results (which we  only assessed
later) corroborated the hypothesis of pernicious anemia.1,2
Because of a constitutional history of microcytosis with nor-
mal  iron stores, an Hb disorder (-thalassemia or Hb variants
not assessed by HPLC after excluding -thalassemia) was
highly suspect. Meanwhile, because these tests are not avail-
able in our institution and as they would not signiﬁcantly
affect the therapeutic approach, they were not performed. In
many cases of hypoproliferative anemia and pancytopenia,
it is also essential to exclude hematopoietic diseases, bone
marrow inﬁltration and inﬂammatory causes.1
Pernicious anemia is most frequent in people with other
autoimmune diseases, mainly thyroid, with anti-thyroid
antibody positivity in about half of patients. So, the onset
of autoimmune diseases should be monitored during the
follow-up.1,2
In this case, the initial study of thyroid function revealed
changes in the thyroid hormone proﬁle. However, as there
were only slight decreases in TSH and FT3, the FT4 and TRH
were normal, anti-thyroid antibodies were negative and there
were no changes in thyroid ultrasound, a diagnosis of NTIS
was established.6,7 Although this entity is usually associated
with serious or critical illness, it can also be found in less seri-
ous diseases as was demonstrated by this case. In fact, the
pathophysiological signiﬁcance of the alterations detected in
NTIS remains controversial, since it is not known whether theologic response to stress which just needs to be followed up, or
whether it is a maladaptive response contributing to a wors-
ening of the disease which needs appropriate treatment.6,7 In
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this case, the TSH level normalized after the acute stress, being
concordant with an adaptive response, highlighting the lack
of usefulness of assessing thyroid hormones in stress.
CA 15.3 is an immunodominant epitope in the extracellu-
lar portion of the membrane bound mucin. The mucin protein,
encoded by the MUC1 gene, is a cell surface transmembrane
glycoprotein, expressed at the apical surface of most epithelia
(such as the mammary  gland) in normal tissue, and seems to
be involved in erythroid differentiation during erythropoiesis.5
In tumors, the mucin protein undergoes proteolytic cleav-
age, and releases the extracellular segment, which has been
identiﬁed as CA 15.3, into the bloodstream.5 Likewise, when
erythroblasts become apoptotic, the CA 15.3 levels increase
due to the release of the mucin fragment and Lewis antigen,
which is also recognized by the antibody that usually binds CA
15.3. Therefore, CA 15.3 levels increase without an underlying
tumor.3,5,10 Studies have shown that serum CA 15.3 levels are
associated with the degree of peripheral hemolysis and inef-
fective erythropoiesis in vitamin B12 deﬁciency and in other
causes of hemolysis, such as thalassemia or sickle cell ane-
mia. CA 15.3 is not related with an increase in the incidence of
breast cancer or other neoplasms over time, on the contrary, it
is one of the tumor markers more  frequently found increased
in non-neoplastic diseases.3,10
Present data do not recommend using tumor markers for
screening and diagnosis due to low sensitivity and speciﬁcity;
the ﬁnding of an increased marker level mandates imaging
studies in order to exclude cancer, which can lead to inappro-
priate and unnecessary investigations.3,4
The treatment of pernicious anemia is based on 4–6
weekly administrations of intramuscular vitamin B12 at a
dose of 1000 g (cyanocobalamin quarterly; hydroxocobal-
amin monthly) after a loading dose. Oral replacement
therapy has not yet been validated in pernicious anemia
and the transfusion of packed red blood cells is usually not
indicated.6,7
Besides the replacement of vitamin B12 stores, it is
important to be vigilant for the co-occurrence of gastric
adenocarcinoma, neuroendocrine tumors and marginal non-
Hodgkin lymphoma by endoscopic examination, because they
are more  frequent in patients with pernicious anemia.1-3 2 0 1 5;3  7(6):414–416
Conclusion
This case illustrates spurious laboratory ﬁndings of mega-
loblastic anemia. Moreover, an extensive laboratory investi-
gation sometimes can be more  confounding than clarifying,
and laboratory abnormalities found in the acute phase of the
disease may lead to unnecessary exams.
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